EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study

S Gerdes iD, M Hoffmann, K Asadullah, B Korge, D Mortazawi, N Krüger, Y Personke iD, S Tabori, M Gomez, S Wegner, F Kreimendahl, F Taut und 1 weitere

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.19296 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von S Gerdes und 12 weiteren Autor:innen. Beteiligte Einrichtung: Psoriasis-Center Kiel, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany. Hauptthemen laut MEDLINE: Psoriasis, Quality of Life, Ustekinumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Janssen-Cilag GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

PERSIST was a prospective, non‐interventional, real‐world study of guselkumab and ustekinumab in adult patients with moderate‐to‐severe plaque psoriasis in Germany.

Objectives

To examine effectiveness, safety and quality‐of‐life (QoL) outcomes to Week (W) 104 of treatment with guselkumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis.

Methods

Patients (≥18 years of age) received guselkumab or ustekinumab as per routine clinical practice. Outcomes to W104 were examined separately in guselkumab and ustekinumab recipients. An ad hoc exploratory analysis of outcomes with guselkumab versus ustekinumab was also performed following propensity score matching.

Results

Overall, 302 and 313 patients received guselkumab and ustekinumab, respectively. Patients in both cohorts experienced improvements in disease activity and QoL that were maintained to W104, with 64.7% and 63.6% of guselkumab‐ and 54.6% and 64.4% of ustekinumab‐treated patients achieving a Psoriasis Area and Severity Index (PASI) 90 response and a Dermatology Life Quality Index (DLQI) 0/1 score, respectively. Propensity score matching yielded well‐balanced baseline characteristics except for prior biologic use, which was higher in guselkumab versus ustekinumab recipients (51.7% vs. 32.0%). Achievement of PASI ≤1 at W104 was more common in guselkumab versus ustekinumab recipients (58.7% vs. 49.7%). The W104 PASI90 response rate was 65.6% with guselkumab and 56.0% with ustekinumab; corresponding rates for PASI100 were 44.3% and 28.5%. In guselkumab recipients, response rates were higher in biologic‐naïve versus biologic‐experienced patients (PASI90, 77.1% vs. 53.4%; PASI100, 55.0% vs. 33.0%). A high level of response for QoL outcomes was observed for both treatments.

Conclusions

Ustekinumab and guselkumab led to improvements in physician‐assessed and patient‐reported outcomes that were sustained for up to 2 years, with no new safety signals identified. Following propensity score matching, greater improvements in PASI outcomes were observed with guselkumab versus ustekinumab. Improvements with guselkumab were highest in biologic‐naïve patients, highlighting the value of early treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisQuality of LifeUstekinumabAntibodies, Monoclonal, HumanizedDermatologic AgentsAntibodies, MonoclonalHumansMaleFemaleMiddle AgedProspective StudiesGermanyAdultTreatment OutcomeSeverity of Illness Index

Substanzen

UstekinumabAntibodies, Monoclonal, HumanizedguselkumabDermatologic AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Psoriasis-Center Kiel, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Dermatology Practice Dr. Matthias Hoffmann, Witten, Germany.
  • Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
  • Prof. Dr. med. Asadullah, Dermatology Practice, Potsdam, Germany.
  • Dermatology Practice Dr. Bernhard Korge, Düren, Germany.
  • Dermatology Practice Dr. Dariusch Mortazawi, Remscheid, Germany.

ORCID-Profile: S Gerdes, Y Personke

Förderung

  • Janssen-Cilag GmbH

Zitieren

APA

Gerdes, S., Hoffmann, M., Asadullah, K., Korge, B., Mortazawi, D., Krüger, N., Personke, Y., Tabori, S., Gomez, M., Wegner, S., Kreimendahl, F., Taut, F., & Sticherling, M. (2025). Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19296

Vancouver

Gerdes S, Hoffmann M, Asadullah K, Korge B, Mortazawi D, Krüger N, et al. Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.19296

BibTeX
@article{Gerdes2025,
  author = {Gerdes, S and Hoffmann, M and Asadullah, K and Korge, B and Mortazawi, D and Krüger, N and Personke, Y and Tabori, S and Gomez, M and Wegner, S and Kreimendahl, F and Taut, F and Sticherling, M},
  title = {Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.19296}
}
Kostenlos starten →